Today: Today, FY2018 EPS Estimates for Johnson & Johnson Cut by Analyst (JNJ)

Today, FY2018 EPS Estimates for Johnson & Johnson Cut by Analyst (JNJ)

Johnson & Johnson (NYSE:JNJ) – Analysts at Jefferies Group cut their FY2018 EPS estimates for Johnson & Johnson in a research report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings of $7.16 per share for the year, down from their prior estimate of $7.30. Jefferies Group has a “Hold” rating and a $115.00 price objective on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.52 EPS.

A number of other analysts have also recently commented on the company. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a research report on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Johnson & Johnson in a report on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a report on Friday, August 5th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Finally, Credit Suisse Group AG reissued a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a report on Monday, September 19th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $120.20.

Johnson & Johnson (NYSE:JNJ) opened at 117.56 on Monday. The company’s 50-day moving average price is $118.72 and its 200-day moving average price is $117.37. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The company has a market capitalization of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Americafirst Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. purchased a new position in Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors own 65.32% of the company’s stock.

About Johnson & Johnson

Related posts

Leave a Comment